Evidence map›Paper›PMID 31781495›Full record

ArticleFrontiers in oncology2019

WMJ-S-001, a Novel Aliphatic Hydroxamate-Based Compound, Suppresses Lymphangiogenesis Through p38mapk-p53-survivin Signaling Cascade.

Shiu-Wen Huang, Hung-Yu Yang, Wei-Jan Huang, Wei-Chuan Chen, Meng-Chieh Yu, Shih-Wei Wang, Ya-Fen Hsu, Ming-Jen Hsu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Lymphangiogenesis: A new strategy for heart disease treatment (Review).International journal of molecular medicine · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Shiu-Wen HuangDepartment of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan.
Hung-Yu YangDivision of Cardiovascular Medicine, Department of Internal Medicine, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan.
Wei-Jan HuangGraduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan.
Wei-Chuan ChenGraduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Meng-Chieh YuDepartment of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Shih-Wei WangDepartment of Medicine, Mackay Medical College, New Taipei City, Taiwan.
Ya-Fen HsuDivision of General Surgery, Department of Surgery, Landseed Hospital, Taoyuan, Taiwan.
Ming-Jen HsuDepartment of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Taipei Medical University · TWKaohsiung Medical University · TWLandseed Hospital · TWTaipei Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

hydroxamatelymphangiogenesislymphatic endothelial cells (LECs)p38p53survivin

Identifiers

PMID31781495
PMCPMC6851263
OpenAlexW2986740466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.